# NCI-sponsored Clinical Trial Research Specialist

> **NIH NIH R50** · UNIVERSITY OF FLORIDA · 2024 · $115,272

## Abstract

ABSTRACT
NCI-sponsored clinical trials represent some of the highest priority clinical trials conducted by the UF Health
Cancer Center (UFHCC). These trials include participation by patients seen at our center as well as those
through our academic research consortium across the entire state of Florida to deliver trial access to where
patients are. The UFHCC is committed to the success of NCI-sponsored clinical trials through robust partnerships
with the National Clinical Trials Network (NCTN) through the Children's Oncology Group (COG), NRG Oncology
as well as the Experimental Therapeutics Clinical Trial Network (ETCTN). This commitment is demonstrated at
multiple levels including, but not limited to, prioritizing investigator participation in NCI-sponsored clinical trials,
facilitating rapid and efficient activation, financially subsidizing the costs of trial conduct, supporting faculty to
attend meetings serving as content experts/committee members, hosting the COG Statistical and Data Center,
embedding expectations for participation into salary support, and providing a mechanism to allow regional
community oncology practices to access trials. My involvement and effort at each of these institutional levels has
resulted in improved productivity, efficiency, and impact. These include my leadership as the inaugural UFHCC
Associate Director for Clinical Research (ADCR), Director of the Experimental Therapeutics Group, and Director
of the GI Oncology Program. Portfolio priority, oversight and enrollments to the NCI-sponsored clinical trials are
a demonstrated institutional priority. Within the NCI-sponsored clinical trial networks, I am also active and provide
impact through administrative leadership. I serve as the NRG Oncology Co-Chair of the GI Committee, Chair of
the Colorectal Cancer Subcommittee, and member of the Communications Committee. I also serve as the
UFHCC institutional PI to the ETCTN and Yale LAO member. I am personally involved in the NCI peer-review
process by which concepts are evaluated for scientific merit, impact, and feasibility prior to being approved as
trials. These reviews occur in the NCI disease-specific Task Forces, specifically, the Esophagogastric,
Hepatobiliary, Pancreatic, Neuroendocrine, Colon, and Rectal-Anal Cancer NCI Task Forces as well as trial final
approval as a voting member of the NCI Gastrointestinal Steering Committee. Through these positions and with
additional contributions, I have actively and positively influenced the current and future landscape of the NCTN
and ETCTN programs, particularly the GI Oncology trial portfolio. My career goals include continued service to
the NCI-sponsored clinical trial networks through leadership, new member engagement and trial
development/completion while simultaneously increasing my institutional engagement through expanded trial
conduct and expanding the next generation of capable and diverse NCI clinical investigators leveraging my
leadership, experience, mentorsh...

## Key facts

- **NIH application ID:** 10915586
- **Project number:** 5R50CA281930-02
- **Recipient organization:** UNIVERSITY OF FLORIDA
- **Principal Investigator:** Thomas J. George
- **Activity code:** R50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $115,272
- **Award type:** 5
- **Project period:** 2023-09-01 → 2028-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10915586

## Citation

> US National Institutes of Health, RePORTER application 10915586, NCI-sponsored Clinical Trial Research Specialist (5R50CA281930-02). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10915586. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*